1. Home
  2. CRVL vs IMNM Comparison

CRVL vs IMNM Comparison

Compare CRVL & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CorVel Corp.

CRVL

CorVel Corp.

HOLD

Current Price

$57.97

Market Cap

2.8B

Sector

Finance

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$20.96

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRVL
IMNM
Founded
1987
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.6B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
CRVL
IMNM
Price
$57.97
$20.96
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$32.80
AVG Volume (30 Days)
140.4K
748.3K
Earning Date
05-21-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.40
EPS
1.53
N/A
Revenue
$895,589,000.00
$6,941,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,127.34
P/E Ratio
$37.73
N/A
Revenue Growth
12.61
N/A
52 Week Low
$44.83
$7.74
52 Week High
$117.22
$27.65

Technical Indicators

Market Signals
Indicator
CRVL
IMNM
Relative Strength Index (RSI) 53.59 36.80
Support Level $51.10 $19.23
Resistance Level $58.74 $22.86
Average True Range (ATR) 1.71 1.07
MACD -0.09 -0.26
Stochastic Oscillator 56.32 0.00

Price Performance

Historical Comparison
CRVL
IMNM

About CRVL CorVel Corp.

CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: